09-02-2023, 07:15 PM
Needed: Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
In this review, we examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled.
As of 2022, after more than 60 years of experience with influenza vaccines, very little improvement in vaccine prevention of infection has been noted.
The vaccines elicit incomplete and short-lived protection against evolving virus variants that escape population immunity.
If data support that mucosal vaccine adjuventation is needed and proves possible, we will need to assess potential pitfalls, including possible toxicity and side effects of repeated high-dose mucosal immunization/adjuventation, and how best to study it in humans.
https://www.cell.com/cell-host-microbe/f...22)00572-8
In this review, we examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled.
As of 2022, after more than 60 years of experience with influenza vaccines, very little improvement in vaccine prevention of infection has been noted.
The vaccines elicit incomplete and short-lived protection against evolving virus variants that escape population immunity.
If data support that mucosal vaccine adjuventation is needed and proves possible, we will need to assess potential pitfalls, including possible toxicity and side effects of repeated high-dose mucosal immunization/adjuventation, and how best to study it in humans.
https://www.cell.com/cell-host-microbe/f...22)00572-8